Epstein-Barr virus in lymphoproliferative processes: An update for the diagnostic pathologist

Advances in Anatomic Pathology

Volumn 16, Issue 1, 2009, Pages 40-55

  Ng, Siok Bian ^a   Khoury, Joseph D ^b,c  

^a NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^b NEVADA CANCER INSTITUTE   (United States)

^c QUEST DIAGNOSTICS NICHOLS INSTITUTE   (United States)

Author keywords

Epstein Barr virus; Leukemia; Lymphocyte; Lymphoma; Lymphoproliferative disorders; Neoplasia; Virus

Indexed keywords

ACQUIRED IMMUNE DEFICIENCY SYNDROME; BURKITT LYMPHOMA; CLASSICAL HODGKIN LYMPHOMA; CLINICAL FEATURE; DISEASE ASSOCIATION; EPITHELIUM TUMOR; EPSTEIN BARR VIRUS; HERPES; HISTOPATHOLOGY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYDROA VACCINIFORME; IMMUNE RESPONSE; IMMUNOCOMPETENT CELL; INFECTIOUS MONONUCLEOSIS; LARGE CELL LYMPHOMA; LYMPHOMATOID GRANULOMATOSIS; LYMPHOPROLIFERATIVE DISEASE; MESENCHYMOMA; NK T CELL LYMPHOMA; NONHUMAN; PATHOGENESIS; PRIMARY EFFUSION LYMPHOMA; PRIORITY JOURNAL; REVIEW; T CELL LYMPHOMA; TRANSPLANTATION; VIROLOGY; WORLD HEALTH ORGANIZATION; B LYMPHOCYTE; CLASSIFICATION; EPITHELIUM CELL; GENE TRANSLOCATION; GENETIC VARIABILITY; GENETICS; ISOLATION AND PURIFICATION; ONCOGENE MYC; PATHOLOGY; PHYSIOLOGY; VIRUS INFECTION; VIRUS LATENCY;

MESSENGER RNA; VIRUS RNA;

B-LYMPHOCYTES; BURKITT LYMPHOMA; EPITHELIAL CELLS; EPSTEIN-BARR VIRUS INFECTIONS; GENES, MYC; GENETIC VARIATION; HERPESVIRUS 4, HUMAN; HUMANS; LYMPHOPROLIFERATIVE DISORDERS; RNA, MESSENGER; RNA, VIRAL; TRANSLOCATION, GENETIC; VIRUS LATENCY;

EID: 59849087443     PISSN: 10724109     EISSN: 15334031     Source Type: Journal    
DOI: 10.1097/PAP.0b013e3181916029     Document Type: Review

References (168)

1. Epstein MA, Achong BG, Barr YM. Virus particles in cultured lymphoblasts from Burkitt's lymphoma. Lancet. 1964;1:702-703.
2. Rickinson A. Epstein-Barr virus. Virus Res. 2002;82:109-113.
3. Henle G, Henle W, Diehl V. Relation of Burkitt's tumorassociated herpes-type virus to infectious mononucleosis. Proc Natl Acad Sci USA. 1968;59:94-101.
4. Chadwick EG, Connor EJ, Hanson IC, et al. Tumors of smooth-muscle origin in HIV-infected children. JAMA. 1990;263:3182-3184.
5. Jones JF, Shurin S, Abramowsky C, et al. T-cell lymphomas containing Epstein-Barr viral DNA in patients with chronic Epstein-Barr virus infections. N Engl J Med. 1988;318: 733-741. (Pubitemid 18092475)
6. Weiss LM, Strickler JG, Warnke RA, et al. Epstein-Barr viral DNA in tissues of Hodgkin's disease. Am J Pathol. 1987;129: 86-91.
7. Ziegler JL, Drew WL, Miner RC, et al. Outbreak of Burkitt'slike lymphoma in homosexual men. Lancet. 1982;2:631-633. (Pubitemid 12056646)
8. zur Hausen H, Schulte-Holthausen H, Klein G, et al. EBV DNA in biopsies of Burkitt tumours and anaplastic carcinomas of the nasopharynx. Nature. 1970;228:1056-1058.
9. Deyrup AT. Epstein-Barr virus-associated epithelial and mesenchymal neoplasms. Hum Pathol. 2008;39:473-483.
10. Swerdlow SH, Campo E, Harris NL, et al, eds. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. 4th ed. Lyon: IARC; 2008.
11. Rickinson AB, Kieff E. Epstein-Barr virus and its replication. In: Fields BN, Knipe DM, Howley PM, eds. Fields Virology. 4th ed. Philadelphia: Lippincott-PhilRaven; 2001:2575-2628.
12. Raab-Traub N, Flynn K. The structure of the termini of the Epstein-Barr virus as a marker of clonal cellular proliferation. Cell. 1986;47:883-889. (Pubitemid 17005061)
13. Fingeroth JD, Weis JJ, Tedder TF, et al. Epstein-Barr virus receptor of human B lymphocytes is the C3d receptor CR2. Proc Natl Acad Sci U S A. 1984;81:4510-4514. (Pubitemid 14055921)
14. Nemerow GR, Wolfert R, McNaughton ME, et al. Identification and characterization of the Epstein-Barr virus receptor on human B lymphocytes and its relationship to the C3d complement receptor (CR2). J Virol. 1985;55:347-351. (Pubitemid 16239720)
15. Li Q, Spriggs MK, Kovats S, et al. Epstein-Barr virus uses HLA class II as a cofactor for infection of B lymphocytes. J Virol. 1997;71:4657-4662. (Pubitemid 27204158)
16. Molesworth SJ, Lake CM, Borza CM, et al. Epstein-Barr virus gH is essential for penetration of B cells but also plays a role in attachment of virus to epithelial cells. J Virol. 2000;74: 6324-6332.
17. Oda T, Imai S, Chiba S, et al. Epstein-Barr virus lacking glycoprotein gp85 cannot infect B cells and epithelial cells. Virology. 2000;276:52-58. (Pubitemid 30792453)
18. Imai S, Nishikawa J, Takada K. Cell-to-cell contact as an efficient mode of Epstein-Barr virus infection of diverse human epithelial cells. J Virol. 1998;72:4371-4378. (Pubitemid 28188743)
19. Fischer E, Delibrias C, Kazatchkine MD. Expression of CR2 (the C3dg/EBV receptor, CD21) on normal human peripheral blood T lymphocytes. J Immunol. 1991;146:865-869.
20. Tsoukas CD, Lambris JD. Expression of CR2/EBV receptors on human thymocytes detected by monoclonal antibodies. Eur J Immunol. 1988;18:1299-1302. (Pubitemid 18225706)
21. Kieff E, Rickinson AB. Epstein-Barr virus and its replication. In: Knipe DM, Howley PM, eds. Fields Virology. 4th ed. Philadelphia: Lippincott Williams & Wilkins Publishers; 2001:2511-2574.
22. Thompson MP, Kurzrock R. Epstein-Barr virus and cancer. Clinical Cancer Research. 2004;10:803-821.
23. Kieff E. Epstein-Barr virus and its replication. In: Fields BN, Knipe DM, Howley PM, eds. Fields Virology. 3rd ed. Philadelphia: Lippincott-PhilaRaven; 1996:2343-2396.
24. Kaiser C, Laux G, Eick D, et al. The proto-oncogene c-myc is a direct target gene of Epstein-Barr virus nuclear antigen 2. Virology. 1999;73:4481-4484. (Pubitemid 29189900)
25. Robertson ES, Lin J, Kieff E. The amino-terminal domains of Epstein-Barr virus nuclear proteins 3A, 3B, and 3C interact with RBPJ(kappa). J Virol. 1996;70:3068-3074. (Pubitemid 26121923)
26. Jiang WQ, Szekely L, Wendel-Hansen V, et al. Co-localization of the retinoblastoma protein and the Epstein-Barr virusencoded nuclear antigen EBNA-5. Experimental Cell Res. 1991;197:314-318. (Pubitemid 121006438)
27. Young LS, Murray PG. Epstein-Barr virus and oncogenesis: from latent genes to tumours. Oncogene. 2003;22:5108-5121. (Pubitemid 37059592)
28. Uchida J, Yasui T, Takaoka-Shichijo Y, et al. Mimicry of CD40 signals by Epstein-Barr virus LMP1 in B lymphocyte responses. Science. 1999;286:300-303. (Pubitemid 29484694)
29. Tao Q, Young LS, Woodman CBJ, et al. Epstein-Barr virus (EBV) and its associated human cancers-Genetics, epigenetics, pathobiology and novel therapeutics. Frontiers in Bioscience. 2006;11:2672-2713. (Pubitemid 43806572)
30. Cohen JI. Epstein-Barr virus infection. New Engl J Med. 2000;343:481-492.
31. Longnecker R. Epstein-Barr virus latency: LMP2, a regulator or means for Epstein-Barr virus persistence? Adv Cancer Res. 2000;79:175-200. (Pubitemid 30228124)
32. Beaufils P, Choquet D, Mamoun RZ, et al. The (YXXL/I)2 signalling motif found in the cytoplasmic segments of the bovine leukaemia virus envelope protein and Epstein- Barr virus latent membrane protein 2A can elicit early and late lymphocyte activation events. EMBO J. 1993;12: 5105-5112. (Pubitemid 23358500)
33. Longnecker R, Miller CL, Miao XQ, et al. The last seven transmembrane and carboxy-terminal cytoplasmic domains of Epstein-Barr virus latent membrane protein 2 (LMP2) are dispensable for lymphocyte infection and growth transformation in vitro. J Virol. 1993;67:2006-2013. (Pubitemid 23088374)
34. Longnecker R, Miller CL, Tomkinson B, et al. Deletion of DNA encoding the first five transmembrane domains of Epstein-Barr virus latent membrane proteins 2A and 2B. J Virol. 1993;67:5068-5074. (Pubitemid 23215993)
35. Speck P, Kline KA, Cheresh P, et al. Epstein-Barr virus lacking latent membrane protein 2 immortalizes B cells with efficiency indistinguishable from that of wild-type virus. J Gen Virol. 1999;80(Pt 8):2193-2203. (Pubitemid 29389158)
36. Thorley-Lawson DA. Epstein-Barr virus: exploiting the immune system. Nat Rev Immunol. 2001;1:75-82.
37. Young L, Alfieri C, Hennessy K, et al. Expression of Epstein- Barr virus transformation-associated genes in tissues of patients with EBV lymphoproliferative disease. N Engl J Med. 1989;321:1080-1085. (Pubitemid 19256661)
38. Rickinson AB, Moss DJ. Human cytotoxic T lymphocyte responses to Epstein-Barr virus infection. Annu Rev Immunol. 1997;15:405-431. (Pubitemid 27169287)
39. Levitskaya J, Coram M, Levitsky V, et al. Inhibition of antigen processing by the internal repeat region of the Epstein-Barr virus nuclear antigen-1. Nature. 1995;375: 685-688.
40. Fahraeus R, Fu HL, Ernberg I, et al. Expression of Epstein- Barr virus-encoded proteins in nasopharyngeal carcinoma. Int J Cancer. 1988;42:329-338. (Pubitemid 18229982)
41. Chiang AK, Tao Q, Srivastava G, et al. Nasal NK- and T-cell lymphomas share the same type of Epstein-Barr virus latency as nasopharyngeal carcinoma and Hodgkin's disease. Int J Cancer. 1996;68:285-290. (Pubitemid 26384128)
42. Deacon EM, Pallesen G, Niedobitek G, et al. Epstein-Barr virus and Hodgkin's disease: transcriptional analysis of virus latency in the malignant cells. J Exp Med. 1993;177:339-349. (Pubitemid 23117083)
43. Hammerschmidt W, Sugden B. Genetic analysis of immortalizing functions of Epstein-Barr virus in human B lymphocytes. Nature. 1989;340:393-397. (Pubitemid 19191606)
44. Doyle MG, Catovsky D, Crawford DH. Infection of leukaemic B lymphocytes by Epstein Barr virus. Leukemia. 1993;7:1858-1864. (Pubitemid 23347307)
45. Rickinson AB, Finerty S, Epstein MA. Interaction of Epstein- Barr virus with leukaemic B cells in vitro. I. Abortive infection and rare cell line establishment from chronic lymphocytic leukaemic cells. Clin Exp Immunol. 1982;50: 347-354. (Pubitemid 13172600)
46. Takada K, Yamamoto K, Osato T. Analysis of the transformation of human lymphocytes by Epstein-Barr virus. II. Abortive response of leukemic cells to the transforming virus. Intervirology. 1980;13:223-231.
47. Walls EV, Doyle MG, Patel KK, et al. Activation and immortalization of leukaemic B cells by Epstein-Barr virus. Int J Cancer. 1989;44:846-853. (Pubitemid 20007982)
48. Fahraeus R, Rymo L, Rhim JS, et al. Morphological transformation of human keratinocytes expressing the LMP gene of Epstein-Barr virus. Nature. 1990;345:447-449. (Pubitemid 20178252)
49. Wang F, Tsang SF, Kurilla MG, et al. Epstein-Barr virus nuclear antigen 2 transactivates latent membrane protein LMP1. J Virol. 1990;64:3407-3416. (Pubitemid 20219546)
50. Tao Q, Srivastava G, Chan AC, et al. Epstein-Barr-virusinfected nasopharyngeal intraepithelial lymphocytes. Lancet. 1995;345:1309-1310.
51. Hudnall SD, Ge Y, Wei L, et al. Distribution and phenotype of Epstein-Barr- virus-infected cells in human pharyngeal tonsils. Mod Pathol. 2005;18:519-527. (Pubitemid 40478115)
52. Chang KL, Chen YY, Shibata D, et al. Description of an in situ hybridization methodology for detection of Epstein-Barr virus RNA in paraffin-embedded tissues, with a survey of normal and neoplastic tissues. Diagn Mol Pathol. 1992;1: 246-255.
53. Laichalk LL, Hochberg D, Babcock GJ, et al. The dispersal of mucosal memory B cells: evidence from persistent EBV infection. Immunity. 2002;16:745-754. (Pubitemid 34626694)
54. Niedobitek G, Herbst H, Young LS, et al. Patterns of Epstein-Barr virus infection in non-neoplastic lymphoid tissue. Blood. 1992;79:2520-2526.
55. Rickinson AB, Kieff E. Epstein-Barr virus. In: Fields BN, Knipe DM, Howley PM, eds. Fields Virology. 3rd ed. Philadelphia: Lippincott-PhilRaven; 1996:2397-2446.
56. Rickinson AB, Moss DJ. Human cytotoxic T lymphocyte responses to Epstein-Barr virus infection. Annu Rev Immunol. 1997;15:405-431. (Pubitemid 27169287)
57. + T cells in acute infectious mononucleosis. Nat Med. 1996;2:906-911.
58. Klein E, Kis LL, Klein G. Epstein-Barr virus infection in humans: from harmless to life endangering virus-lymphocyte interactions. Oncogene. 2007;26:1297-1305. (Pubitemid 46328467)
59. Moore KW, Vieira P, Fiorentino DF, et al. Homology of cytokine synthesis inhibitory factor (IL-10) to the Epstein- Barr virus gene BCRFI. Science. 1990;248:1230-1234. (Pubitemid 20209685)
60. Cohen JI, Lekstrom K. Epstein-Barr virus BARF1 protein is dispensable for B-cell transformation and inhibits alpha interferon secretion from mononuclear cells. J Virol. 1999;73: 7627-7632. (Pubitemid 29383247)
61. Henderson S, Huen D, Rowe M, et al. Epstein-Barr viruscoded BHRF1 protein, a viral homologue of Bcl-2, protects human B cells from programmed cell death. Proc Nat Acad Sci USA. 1993;90:8479-8483. (Pubitemid 23277692)
62. Klein G, Svedmyr E, Jondal M, et al. EBV-determined nuclear antigen (EBNA)-positive cells in the peripheral blood of infectious mononucleosis patients. Int J Cancer. 1976;17: 21-26.
63. McAulay KA, Higgins CD, Macsween KF, et al. HLA class I polymorphisms are associated with development of infectious mononucleosis upon primary EBV infection. J Clin Invest. 2007;117:3042-3048.
64. Virelizier JL, Lenoir G, Griscelli C. Persistent Epstein-Barr virus infection in a child with hypergammaglobulinaemia and immunoblastic proliferation associated with a selective defect in immune interferon secretion. Lancet. 1978;2:231-234. (Pubitemid 8400354)
65. Kanegane H, Bhatia K, Gutierrez M, et al. A syndrome of peripheral blood T-cell infection with Epstein-Barr virus (EBV) followed by EBV-positive T-cell lymphoma. Blood. 1998;91:2085-2091. (Pubitemid 28185512)
66. Quintanilla-Martinez L, Kumar S, Fend F, et al. Fulminant EBV(+) T-cell lymphoproliferative disorder following acute/ chronic EBV infection: a distinct clinicopathologic syndrome. Blood. 2000;96:443-451. (Pubitemid 30463361)
67. Kimura H, Morishima T, Kanegane H, et al. Prognostic factors for chronic active Epstein-Barr virus infection. J Infect Dis. 2003;187:527-533. (Pubitemid 36250015)
68. Kimura H, Hoshino Y, Kanegane H, et al. Clinical and virologic characteristics of chronic active Epstein-Barr virus infection. Blood. 2001;98:280-286.
69. Suzuki K, Ohshima K, Karube K, et al. Clinicopathological states of Epstein-Barr virus-associated T/NK-cell lymphoproliferative disorders (severe chronic active EBV infection) of children and young adults. Int J Oncol. 2004;24:1165-1174.
70. Ohshima K, Suzumiya J, Ohga S, et al. Integrated Epstein- Barr virus (EBV) and chromosomal abnormality in chronic active EBV infection. Int J Cancer. 1997;71:943-947. (Pubitemid 27252872)
71. Kikuta H, Nakanishi M, Sakiyama Y, et al. Chronic active Epstein-Barr virus (EBV) infection is associated with clonotypic intracellular terminal regions of the EBV. J Infect Dis. 1989;160:546-547.
72. Zhang Y, Nagata H, Ikeuchi T, et al. Common cytological and cytogenetic features of Epstein-Barr virus (EBV)-positive natural killer (NK) cells and cell lines derived from patients with nasal T/NK-cell lymphomas, chronic active EBV infection and hydroa vacciniforme-like eruptions. Br J Haematol. 2003;121:805-814. (Pubitemid 36718199)
73. Yachie A, Kanegane H, Kasahara Y. Epstein-Barr virusassociated T-/natural killer cell lymphoproliferative diseases. Semin Hematol. 2003;40:124-132. (Pubitemid 36461090)
74. Quintanilla-Martinez L, Kimura H, Jaffe ES. EBV-positive Tcell lymphoproliferative disorders of childhood. In: Swerdlow SH, Campo E, Harris NL, et al, eds. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. 4th ed. Lyon: IARC Press; 2008:278-280.
75. Leoncini L, Raphael M, Stein H, et al. Burkitt lymphoma. In: Swerdlow SH, Campo E, Harris NL, et al, eds. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. Lyon: IARC; 2008:262-264.
76. Vockerodt M, Morgan S, Kuo M, et al. The Epstein-Barr virus oncoprotein, latent membrane protein-1, reprograms germinal centre B cells towards a Hodgkin's Reed-Sternberglike phenotype. J Pathol. 2008;216:83-92.
77. Navarro A, Gaya A, Martinez A, et al. MicroRNA expression profiling in classic Hodgkin lymphoma. Blood. 2008;111:2825-2832.
78. Diepstra A, Niens M, Vellenga E, et al. Association with HLA class I in Epstein-Barr-virus-positive and with HLA class III in Epstein-Barr-virus- negative Hodgkin's lymphoma. Lancet. 2005;365:2216-2224. (Pubitemid 40853915)
79. Niens M, Jarrett RF, Hepkema B, et al. HLA-A*02 is associated with a reduced risk and HLA-A*01 with an increased risk of developing EBV+ Hodgkin lymphoma. Blood. 2007;110:3310-3315. (Pubitemid 350106324)
80. Glavina-Durdov M, Jakic-Razumovic J, Capkun V, et al. Assessment of the prognostic impact of the Epstein-Barr virus-encoded latent membrane protein-1 expression in Hodgkin's disease. Br J Cancer. 2001;84:1227-1234. (Pubitemid 32511341)
81. Krugmann J, Tzankov A, Gschwendtner A, et al. Longer failure-free survival interval of Epstein-Barr virus-associated classical Hodgkin's lymphoma: a single-institution study. Mod Pathol. 2003;16:566-573. (Pubitemid 36718438)
82. Kuppers R. Molecular biology of Hodgkin's lymphoma. Adv Cancer Res. 2002;84:277-312.
83. Kanzler H, Kuppers R, Hansmann ML, et al. Hodgkin and Reed-Sternberg cells in Hodgkin's disease represent the outgrowth of a dominant tumor clone derived from (crippled) germinal center B cells. J Exp Med. 1996;184:1495-1505. (Pubitemid 26354704)
84. Marafioti T, Hummel M, Foss HD, et al. Hodgkin and Reed- Sternberg cells represent an expansion of a single clone originating from a germinal center B-cell with functional immunoglobulin gene rearrangements but defective immunoglobulin transcription. Blood. 2000;95:1443-1450. (Pubitemid 30099859)
85. Theil J, Laumen H, Marafioti T, et al. Defective octamerdependent transcription is responsible for silenced immunoglobulin transcription in Reed-Sternberg cells. Blood. 2001;97: 3191-3196.
86. Bargou RC, Emmerich F, Krappmann D, et al. Constitutive nuclear factor-kappaB-RelA activation is required for proliferation and survival of Hodgkin's disease tumor cells. J Clin Invest. 1997;100:2961-2969. (Pubitemid 28022832)
87. Hammarskjold ML, Simurda MC. Epstein-Barr virus latent membrane protein transactivates the human immunodefi- ciency virus type 1 long terminal repeat through induction of NF-kappa B activity. J Virol. 1992;66:6496-6501.
88. Caldwell RG, Wilson JB, Anderson SJ, et al. Epstein-Barr virus LMP2A drives B cell development and survival in the absence of normal B cell receptor signals. Immunity. 1998;9: 405-411.
89. Cabannes E, Khan G, Aillet F, et al. Mutations in the IkBa gene in Hodgkin's disease suggest a tumour suppressor role for IkappaBalpha. Oncogene. 1999;18:3063-3070. (Pubitemid 29261226)
90. Jungnickel B, Staratschek-Jox A, Brauninger A, et al. Clonal deleterious mutations in the IkappaBalpha gene in the malignant cells in Hodgkin's lymphoma. J Exp Med. 2000; 191:395-402. (Pubitemid 30060929)
91. Martin-Subero JI, Gesk S, Harder L, et al. Recurrent involvement of the REL and BCL11A loci in classical Hodgkin lymphoma. Blood. 2002;99:1474-1477. (Pubitemid 34547107)
92. Horie R, Watanabe T, Morishita Y, et al. Ligand-independent signaling by overexpressed CD30 drives NF-kappaB activation in Hodgkin-Reed-Sternberg cells. Oncogene. 2002;21:2493-2503. (Pubitemid 34438102)
93. Jaffe ES, Wilson WH. Lymphomatoid granulomatosis. In: Jaffe ES, Harris NL, Stein H, et al, eds. World Health Organization Classification of Tumors Pathology and Genetics of Tumors of Hematopoietic and Lymphoid Tissues. Lyon: IARC Press; 2001:185-187.
94. Katzenstein AL, Carrington CB, Liebow AA. Lymphomatoid granulomatosis: a clinicopathologic study of 152 cases. Cancer. 1979;43:360-373. (Pubitemid 9128841)
95. Guinee D Jr, Jaffe E, Kingma D, et al. Pulmonary lymphomatoid granulomatosis. Evidence for a proliferation of Epstein-Barr virus infected B-lymphocytes with a prominent T-cell component and vasculitis. Am J Surg Pathol. 1994;18: 753-764. (Pubitemid 24229397)
96. Myers JL, Kurtin PJ, Katzenstein AL, et al. Lymphomatoid granulomatosis. Evidence of immunophenotypic diversity and relationship to Epstein-Barr virus infection. Am J Surg Pathol. 1995;19:1300-1312.
97. Nicholson AG, Wotherspoon AC, Diss TC, et al. Lymphomatoid granulomatosis: evidence that some cases represent Epstein-Barr virus-associated B-cell lymphoma. Histopathology. 1996;29:317-324.
98. Wilson WH, Kingma DW, Raffeld M, et al. Association of lymphomatoid granulomatosis with Epstein-Barr viral infection of B lymphocytes and response to interferon-alpha 2b. Blood. 1996;87:4531-4537. (Pubitemid 26162358)
99. Lipford EH Jr, Margolick JB, Longo DL, et al. Angiocentric immunoproliferative lesions: a clinicopathologic spectrum of post-thymic T-cell proliferations. Blood. 1988;72:1674-1681.
100. Taniere P, Thivolet-Bejui F, Vitrey D, et al. Lymphomatoid granulomatosis-a report on four cases: evidence for B phenotype of the tumoral cells. Eur Respir J. 1998;12:102-106. (Pubitemid 28325661)
101. Chan JKC, Aozasa K, Gaulard P. DLBCL associated with chronic inflammation. In: Swerdlow SH, Campo E, Harris NL, et al, eds. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. Lyon: IARC; 2008:245-246.
102. Iuchi K, Aozasa K, Yamamoto S, et al. Non-Hodgkin's lymphoma of the pleural cavity developing from longstanding pyothorax. Summary of clinical and pathological findings in thirty-seven cases. Jpn J Clin Oncol. 1989;19: 249-257.
103. Iuchi K, Ichimiya A, Akashi A, et al. Non-Hodgkin's lymphoma of the pleural cavity developing from long-standing pyothorax. Cancer. 1987;60:1771-1775. (Pubitemid 17139928)
104. Nakatsuka S, Yao M, Hoshida Y, et al. Pyothorax-associated lymphoma: a review of 106 cases. J Clin Oncol. 2002;20: 4255-4260. (Pubitemid 35191029)
105. Fukayama M, Hayashi Y, Ooba T, et al. Pyothoraxassociated lymphoma: development of Epstein-Barr virusassociated lymphoma within the inflammatory cavity. Pathol Int. 1995;45:825-831.
106. Fukayama M, Ibuka T, Hayashi Y, et al. Epstein-Barr virus in pyothorax-associated pleural lymphoma. Am J Pathol. 1993;143:1044-1049. (Pubitemid 24070546)
107. Narimatsu H, Ota Y, Kami M, et al. Clinicopathological features of pyothorax-associated lymphoma; a retrospective survey involving 98 patients. Ann Oncol. 2007;18:122-128. (Pubitemid 46152511)
108. Oyama T, Ichimura K, Suzuki R, et al. Senile EBV+ B-cell lymphoproliferative disorders: a clinicopathologic study of 22 patients. Am J Surg Pathol. 2003;27:16-26. (Pubitemid 36014895)
109. Nakamura S, Jaffe ES, Swerdlow SH. EBV positive diffuse large B-cell lymphoma of the elderly. In: Swerdlow SH, Campo E, Harris NL, et al, eds. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. 4th ed. Lyon: IARC Press; 2008:243-244.
110. Oyama T, Yamamoto K, Asano N, et al. Age-related EBVassociated B-cell lymphoproliferative disorders constitute a distinct clinicopathologic group: a study of 96 patients. Clin Cancer Res. 2007;13:5124-5132. (Pubitemid 47502080)
111. Shimoyama Y, Yamamoto K, Asano N, et al. Age-related Epstein-Barr virus-associated B-cell lymphoproliferative disorders: special references to lymphomas surrounding this newly recognized clinicopathologic disease. Cancer Sci. 2008; 99:1085-1091. (Pubitemid 351676618)
112. Chan JKC, Quintanilla-Martinez L, Ferry JA, et al. Extranodal NK/T-cell lymphoma, nasal type. In: Swerdlow SH, Campo E, Harris NL, et al, eds. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. 4th ed. Lyon: IARC Press; 2008:285-288.
113. Chan JK, Sin VC, Wong KF, et al. Nonnasal lymphoma expressing the natural killer cell marker CD56: a clinicopathologic study of 49 cases of an uncommon aggressive neoplasm. Blood. 1997;89:4501-4513.
114. Hasserjian RP, Harris NL. NK-cell lymphomas and leukemias: a spectrum of tumors with variable manifestations and immunophenotype. Am J Clin Pathol. 2007;127: 860-868.
115. Jaffe ES, Costa J, Fauci AS, et al. Malignant lymphoma and erythrophagocytosis simulating malignant histiocytosis. Am J Med. 1983;75:741-749.
116. Ho FC, Srivastava G, Loke SL, et al. Presence of Epstein- Barr virus DNA in nasal lymphomas of B and 'T' cell type. Hematol Oncol. 1990;8:271-281.
117. Tao Q, Ho FC, Loke SL, et al. Epstein-Bar virus is localized in the tumour cells of nasal lymphomas of NK, T or B cell type. Int J Cancer. 1995;60:315-320.
118. Xu ZG, Iwatsuki K, Oyama N, et al. The latency pattern of Epstein-Barr virus infection and viral IL-10 expression in cutaneous natural killer/T-cell lymphomas. Br J Cancer. 2001;84:920-925. (Pubitemid 32385835)
119. Ng SB, Lai KW, Murugaya S, et al. Nasal-type extranodal natural killer/T-cell lymphomas: a clinicopathologic and genotypic study of 42 cases in Singapore. Mod Pathol. 2004; 17:1097-1107. (Pubitemid 39128236)
120. Chiang AK, Srivastava G, Lau PW, et al. Differences in T-cell-receptor gene rearrangement and transcription in nasal lymphomas of natural killer and T-cell types: implications on cellular origin. Hum Pathol. 1996;27:701-707. (Pubitemid 26240323)
121. Sun HS, Su IJ, Lin YC, et al. A 2.6 Mb interval on chromosome 6q25.2-q25.3 is commonly deleted in human nasal natural killer/T-cell lymphoma. Br J Haematol. 2003;122:590-599.
122. Siu LL, Chan V, Chan JK, et al. Consistent patterns of allelic loss in natural killer cell lymphoma. Am J Pathol. 2000;157: 1803-1809.
123. Ko YH, Ree HJ, Kim WS, et al. Clinicopathologic and genotypic study of extranodal nasal-type natural killer/T-cell lymphoma and natural killer precursor lymphoma among Koreans. Cancer. 2000;89:2106-2116.
124. Lin CW, Chen YH, Chuang YC, et al. CD94 transcripts imply a better prognosis in nasal-type extranodal NK/T-cell lymphoma. Blood. 2003;102:2623-2631.
125. Kim SJ, Kim BS, Choi CW, et al. Ki-67 expression is predictive of prognosis in patients with stage I/II extranodal NK/T-cell lymphoma, nasal type. Ann Oncol. 2007;18: 1382-1387.
126. Hsieh PP, Tung CL, Chan AB, et al. EBV viral load in tumor tissue is an important prognostic indicator for nasal NK/T-cell lymphoma. Am J Clin Pathol. 2007;128:579-584.
127. Ishii H, Ogino T, Berger C, et al. Clinical usefulness of serum EBV DNA levels of BamHI W and LMP1 for Nasal NK/Tcell lymphoma. J Med Virol. 2007;79:562-572. (Pubitemid 46564355)
128. Chan JKC. Tumors of the lymphoreticular system. In: Fletcher CDM, ed. Diagnostic Histopathology of Tumors. 3rd ed. Philadelphia, USA: Churchill Livingstone Elsevier; 2007:1139-1361.
129. Imamura N, Kusunoki Y, Kawa-Ha K, et al. Aggressive natural killer cell leukaemia/lymphoma: report of four cases and review of the literature. Possible existence of a new clinical entity originating from the third lineage of lymphoid cells. Br J Haematol. 1990;75:49-59. (Pubitemid 20157979)
130. Mori N, Yamashita Y, Tsuzuki T, et al. Lymphomatous features of aggressive NK cell leukaemia/lymphoma with massive necrosis, haemophagocytosis and EB virus infection. Histopathology. 2000;37:363-371. (Pubitemid 30781591)
131. Quintanilla-Martinez L, Jaffe ES. Commentary: aggressive NK cell lymphomas: insights into the spectrum of NK cell derived malignancies. Histopathology. 2000;37:372-374. (Pubitemid 30781592)
132. Nava VE, Jaffe ES. The pathology of NK-cell lymphomas and leukemias. Adv Anat Pathol. 2005;12:27-34.
133. Chan JK. Natural killer cell neoplasms. Anat Pathol. 1998;3: 77-145.
134. Soler J, Bordes R, Ortno F, et al. Aggressive natural killer cell leukaemia/lymphoma in two patients with lethal midline granuloma. Br J Haematol. 1994;86:659-662. (Pubitemid 24199061)
135. Nakashima Y, Tagawa H, Suzuki R, et al. Genome-wide array-based comparative genomic hybridization of natural killer cell lymphoma/leukemia: different genomic alteration patterns of aggressive NK-cell leukemia and extranodal Nk/ T-cell lymphoma, nasal type. Genes Chromosomes Cancer. 2005;44:247-255. (Pubitemid 41397093)
136. Siu LL, Wong KF, Chan JK, et al. Comparative genomic hybridization analysis of natural killer cell lymphoma/leukemia. Recognition of consistent patterns of genetic alterations. Am J Pathol. 1999;155:1419-1425.
137. Wong KF, Zhang YM, Chan JK. Cytogenetic abnormalities in natural killer cell lymphoma/leukaemia-is there a consistent pattern? Leukemia Lymphoma. 1999;34:241-250.
138. Ohshima K, Kimura H, Yoshino T, et al. Proposed categorization of pathological states of EBV-associated T/ natural killer-cell lymphoproliferative disorder (LPD) in children and young adults: overlap with chronic active EBV infection and infantile fulminant EBV T-LPD. Pathol Int. 2008;58:209-217. (Pubitemid 351347666)
139. Cho KH, Kim CW, Heo DS, et al. Epstein-Barr virusassociated peripheral T-cell lymphoma in adults with hydroa vacciniforme-like lesions. Clin Exp Dermatol. 2001;26: 242-247.
140. Iwatsuki K, Xu Z, Takata M, et al. The association of latent Epstein-Barr virus infection with hydroa vacciniforme. Br J Dermatol. 1999;140:715-721. (Pubitemid 29191396)
141. Kimura H. Pathogenesis of chronic active Epstein-Barr virus infection: is this an infectious disease, lymphoproliferative disorder, or immunodeficiency? Rev Med Virol. 2006;16:251-261. (Pubitemid 44140721)
142. + T cells. Leukemia. 1992;6:952-956.
143. Su IJ, Lin KH, Chen CJ, et al. Epstein-Barr virus-associated peripheral T-cell lymphoma of activated CD8 phenotype. Cancer. 1990;66:2557-2562.
144. Noma T, Kou K, Yoshizawa I, et al. Monoclonal proliferation of Epstein-Barr virus-infected T cells in a patient with virus-associated haemophagocytic syndrome. Eur J Pediatr. 1994;153:734-738. (Pubitemid 24300473)
145. Tazawa Y, Nishinomiya F, Noguchi H, et al. A case of fatal infectious mononucleosis presenting with fulminant hepatic failure associated with an extensive CD8-positive lymphocyte infiltration in the liver. Hum Pathol. 1993;24:1135-1139. (Pubitemid 23306247)
146. Kikuta H, Sakiyama Y, Matsumoto S, et al. Fatal Epstein- Barr virus-associated hemophagocytic syndrome. Blood. 1993;82:3259-3264. (Pubitemid 23356693)
147. Kasahara Y, Yachie A, Takei K, et al. Differential cellular targets of Epstein-Barr virus (EBV) infection between acute EBV-associated hemophagocytic lymphohistiocytosis and chronic active EBV infection. Blood. 2001;98:1882-1888.
148. Su IJ, Chen RL, Lin DT, et al. Epstein-Barr virus (EBV) infects T lymphocytes in childhood EBV-associated hemophagocytic syndrome in Taiwan. Am J Pathol. 1994;144:1219-1225. (Pubitemid 24172084)
149. Jaffe ES, Krenacs L, Raffeld M. Classification of cytotoxic T-cell and natural killer cell lymphomas. Semin Hematol. 2003;40:175-184. (Pubitemid 36842595)
150. Warnke RA, Jones D, Hsi ED. Morphologic and immunophenotypic variants of nodal T-cell lymphomas and T-cell lymphoma mimics. Am J Clin Pathol. 2007;127:511-527.
151. Dorfman DM, Brown JA, Shahsafaei A, et al. Programmed death-1 (PD-1) is a marker of germinal center-associated T cells and angioimmunoblastic T-cell lymphoma. Am J Surg Pathol. 2006;30:802-810. (Pubitemid 44264969)
152. Zettl A, Lee SS, Rüdiger T, et al. Epstein-Barr virusassociated B-cell lymphoproliferative disorders in angloimmunoblastic T-cell lymphoma and peripheral T-cell lymphoma, unspecified. Am J Clin Pathol. 2002;117:368-379. (Pubitemid 34226071)
153. Quintanilla-Martinez L, Fend F, Moguel LR, et al. Peripheral T-cell lymphoma with Reed-Sternberg-like cells of B-cell phenotype and genotype associated with Epstein-Barr virus infection. Am J Surg Pathol. 1999;23:1233-1240. (Pubitemid 29474593)
154. Chadburn A, Suciu-Foca N, Cesarman E, et al. Posttransplantation lymphoproliferative disorders arising in solid organ transplant recipients are usually of recipient origin. Am J Pathol. 1995;147:1862-1870.
155. Knowles DM, Cesarman E, Chadburn A, et al. Correlative morphologic and molecular genetic analysis demonstrates three distinct categories of posttransplantation lymphoproliferative disorders. Blood. 1995;85:552-565.
156. Polack A, Hortnagel K, Pajic A, et al. c-myc activation renders proliferation of Epstein-Barr virus (EBV)-transformed cells independent of EBV nuclear antigen 2 and latent membrane protein 1. Proc Natl Acad Sci USA. 1996;93: 10411-10416. (Pubitemid 26314636)
157. Cesarman E, Chadburn A, Liu YF, et al. BCL-6 gene mutations in posttransplantation lymphoproliferative disorders predict response to therapy and clinical outcome. Blood. 1998;92:2294-2302. (Pubitemid 28452970)
158. Raphael M, Borisch B, Jaffe ES. Lymphomas associated with infection by the human immunodeficiency virus (HIV). In: Jaffe ES, Harris NL, Stein H, et al, eds. World Health Organization Classification of Tumors Pathology and Genetics of Tumors of Hematopoietic and Lymphoid Tissues. Lyon: IARC Press; 2001.
159. Beral V, Peterman T, Berkelman R, et al. AIDS-associated non-Hodgkin lymphoma. Lancet. 1991;337:805-809.
160. Dong HY, Scadden DT, de Leval L, et al. Plasmablastic lymphoma in HIV-positive patients: an aggressive Epstein- Barr virus-associated extramedullary plasmacytic neoplasm. Am J Surg Pathol. 2005;29:1633-1641.
161. Folk GS, Abbondanzo SL, Childers EL, et al. Plasmablastic lymphoma: a clinicopathologic correlation. Ann Diagn Pathol. 2006;10:8-12.
162. Rochford R, Hobbs MV, Garnier JL, et al. Plasmacytoid differentiation of Epstein-Barr virus-transformed B cells in vivo is associated with reduced expression of viral latent genes. Proc Natl Acad Sci U S A. 1993;90:352-356. (Pubitemid 23010308)
163. Fan W, Bubman D, Chadburn A, et al. Distinct subsets of primary effusion lymphoma can be identified based on their cellular gene expression profile and viral association. J Virol. 2005;79:1244-1251. (Pubitemid 40053906)
164. Szekely L, Chen F, Teramoto N, et al. Restricted expression of Epstein-Barr virus (EBV)-encoded, growth transformationassociated antigens in an EBV and human herpesvirus type 8- carrying body cavity lymphoma line. J Gen Virol. 1998;79(Pt 6):1445-1452. (Pubitemid 28258455)
165. Matolcsy A, Nador RG, Cesarman E, et al. Immunoglobulin VH gene mutational analysis suggests that primary effusion lymphomas derive from different stages of B cell maturation. Am J Pathol. 1998;153:1609-1614. (Pubitemid 28509918)
166. Du MQ, Diss TC, Liu H, et al. KSHV- and EBV-associated germinotropic lymphoproliferative disorder. Blood. 2002;100: 3415-3418. (Pubitemid 35217095)
167. Isaacson PG, Campo E, Harris NL. Large B-cell lymphoma arising in HHV8-associated multicentric Castleman disease. In: Swerdlow SH, Campo E, Harris NL, et al, eds. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissue. 4th ed. Lyon: IARC; 2008:258-259.
168. Morice WG. The immunophenotypic attributes of NK cells and NK-cell lineage lymphoproliferative disorders. Am J Clin Pathol. 2007;127:881-886.